Cargando…

Liposomal drug delivery to manage nontuberculous mycobacterial pulmonary disease and other chronic lung infections

Nontuberculous mycobacterial (NTM) pulmonary disease is a chronic respiratory infection associated with declining lung function, radiological deterioration and significantly increased morbidity and mortality. Patients often have underlying lung conditions, particularly bronchiectasis and COPD. NTM p...

Descripción completa

Detalles Bibliográficos
Autores principales: Chalmers, James D., van Ingen, Jakko, van der Laan, Roald, Herrmann, Jean-Louis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488898/
https://www.ncbi.nlm.nih.gov/pubmed/34289985
http://dx.doi.org/10.1183/16000617.0010-2021
_version_ 1784792763864186880
author Chalmers, James D.
van Ingen, Jakko
van der Laan, Roald
Herrmann, Jean-Louis
author_facet Chalmers, James D.
van Ingen, Jakko
van der Laan, Roald
Herrmann, Jean-Louis
author_sort Chalmers, James D.
collection PubMed
description Nontuberculous mycobacterial (NTM) pulmonary disease is a chronic respiratory infection associated with declining lung function, radiological deterioration and significantly increased morbidity and mortality. Patients often have underlying lung conditions, particularly bronchiectasis and COPD. NTM pulmonary disease is difficult to treat because mycobacteria can evade host defences and antimicrobial therapy through extracellular persistence in biofilms and sequestration into macrophages. Management of NTM pulmonary disease remains challenging and outcomes are often poor, partly due to limited penetration of antibiotics into intracellular spaces and biofilms. Efficient drug delivery to the site of infection is therefore a key objective of treatment, but there is high variability in lung penetration by antibiotics. Inhalation is the most direct route of delivery and has demonstrated increased efficacy of antibiotics like amikacin compared with systemic administration. Liposomes are small, artificial, enclosed spherical vesicles, in which drug molecules can be encapsulated to provide controlled release, with potentially improved pharmacokinetics and reduced toxicity. They are especially useful for drugs where penetration of cell membranes is essential. Inhaled delivery of liposomal drug solutions can therefore facilitate direct access to macrophages in the lung where the infecting NTM may reside. A range of liposomal drugs are currently being evaluated in respiratory diseases.
format Online
Article
Text
id pubmed-9488898
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-94888982022-11-14 Liposomal drug delivery to manage nontuberculous mycobacterial pulmonary disease and other chronic lung infections Chalmers, James D. van Ingen, Jakko van der Laan, Roald Herrmann, Jean-Louis Eur Respir Rev Review Nontuberculous mycobacterial (NTM) pulmonary disease is a chronic respiratory infection associated with declining lung function, radiological deterioration and significantly increased morbidity and mortality. Patients often have underlying lung conditions, particularly bronchiectasis and COPD. NTM pulmonary disease is difficult to treat because mycobacteria can evade host defences and antimicrobial therapy through extracellular persistence in biofilms and sequestration into macrophages. Management of NTM pulmonary disease remains challenging and outcomes are often poor, partly due to limited penetration of antibiotics into intracellular spaces and biofilms. Efficient drug delivery to the site of infection is therefore a key objective of treatment, but there is high variability in lung penetration by antibiotics. Inhalation is the most direct route of delivery and has demonstrated increased efficacy of antibiotics like amikacin compared with systemic administration. Liposomes are small, artificial, enclosed spherical vesicles, in which drug molecules can be encapsulated to provide controlled release, with potentially improved pharmacokinetics and reduced toxicity. They are especially useful for drugs where penetration of cell membranes is essential. Inhaled delivery of liposomal drug solutions can therefore facilitate direct access to macrophages in the lung where the infecting NTM may reside. A range of liposomal drugs are currently being evaluated in respiratory diseases. European Respiratory Society 2021-07-21 /pmc/articles/PMC9488898/ /pubmed/34289985 http://dx.doi.org/10.1183/16000617.0010-2021 Text en Copyright ©The authors 2021 https://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org (mailto:permissions@ersnet.org)
spellingShingle Review
Chalmers, James D.
van Ingen, Jakko
van der Laan, Roald
Herrmann, Jean-Louis
Liposomal drug delivery to manage nontuberculous mycobacterial pulmonary disease and other chronic lung infections
title Liposomal drug delivery to manage nontuberculous mycobacterial pulmonary disease and other chronic lung infections
title_full Liposomal drug delivery to manage nontuberculous mycobacterial pulmonary disease and other chronic lung infections
title_fullStr Liposomal drug delivery to manage nontuberculous mycobacterial pulmonary disease and other chronic lung infections
title_full_unstemmed Liposomal drug delivery to manage nontuberculous mycobacterial pulmonary disease and other chronic lung infections
title_short Liposomal drug delivery to manage nontuberculous mycobacterial pulmonary disease and other chronic lung infections
title_sort liposomal drug delivery to manage nontuberculous mycobacterial pulmonary disease and other chronic lung infections
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488898/
https://www.ncbi.nlm.nih.gov/pubmed/34289985
http://dx.doi.org/10.1183/16000617.0010-2021
work_keys_str_mv AT chalmersjamesd liposomaldrugdeliverytomanagenontuberculousmycobacterialpulmonarydiseaseandotherchroniclunginfections
AT vaningenjakko liposomaldrugdeliverytomanagenontuberculousmycobacterialpulmonarydiseaseandotherchroniclunginfections
AT vanderlaanroald liposomaldrugdeliverytomanagenontuberculousmycobacterialpulmonarydiseaseandotherchroniclunginfections
AT herrmannjeanlouis liposomaldrugdeliverytomanagenontuberculousmycobacterialpulmonarydiseaseandotherchroniclunginfections